Relación de las 20 publicaciones más relevantes

  1. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017 Jun;76(6):948-959. doi: 10.1136/annrheumdis-2016-210602. Epub 2016 Dec 15. PubMed PMID: 27979873.
  2. Álvaro-Gracia JM, Jover JA, García-Vicuña R, Carreño L, Alonso A, Marsal S, Blanco F, Martínez-Taboada VM, Taylor P, Martín-Martín C, DelaRosa O, Tagarro I, Díaz-González F. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017 Jan;76(1):196-202. doi: 10.1136/annrheumdis-2015-208918. Epub 2016 Jun 7. PubMed PMID: 27269294.
  3. Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, Fernández-Nebro A, Ferraz-Amaro I, Gómez-Reino JJ, González-Álvaro I, Martín-Mola E, Martínez-Taboada VM, Ortiz AM, Tornero J, Marsal S, Moreno-Muelas JV. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol Clin. 2015 Sep-Oct;11(5):279-94. doi: 10.1016/j.reuma.2015.05.001. Epub 2015 Jun 6. English, Spanish. PubMed PMID: 26051464.
  4. Bykerk VP, Östör AJ, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Graninger W, Bensen W, Nurmohamed MT, Krause A, Bernasconi C, Aassi M, Sibilia J. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol. 2015 Mar;34(3):563-71. doi: 10.1007/s10067-014-2857-y. Epub 2015 Jan 22. Erratum in: Clin Rheumatol. 2015 Jul;34(7):1321. PubMed PMID: 25604316; PubMed Central PMCID: PMC4348534.
  5. Augustin M, Alvaro-Gracia JM, Bagot M, Hillmann O, van de Kerkhof PC, Kobelt G, Maccarone M, Naldi L, Schellekens H. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol. 2012 Jul;26 Suppl 4:1-16. doi: 10.1111/j.1468-3083.2012.04576.x. PubMed PMID: 22725729.
  6. Bykerk VP, Ostör AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, Bensen W, Nurmohamed MT, Krause A, Bernasconi C, Stancati A, Sibilia J. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis. 2012 Dec;71(12):1950-4. doi: 10.1136/annrheumdis-2011-201087. Epub 2012 May 21. PubMed PMID: 22615456; PubMed Central PMCID: PMC3595980.
  7. Martín Mola E, Hernández B, García-Arias M, Alvaro-Gracia JM, Balsa A, Reino JG, Marenco de la Fuente JL, Martínez-Taboada V, Ivorra JA, Sanmartí R; el grupo de Expertos en Rituximab. [Consensus on the Use of Rituximab in Rheumatoid Arthritis. A document with evidence-based recommendations. Grupo de Expertos en Rituximab. ]. Reumatol Clin. 2011 Jan-Feb;7(1):30-44. doi: 10.1016/j.reuma.2010.11.002. Epub 2010 Dec 17. Spanish. PubMed PMID: 21794777.
  8. Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, Wolfe F, Schwartzman S, Furfaro N, Kavanaugh A. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 2010 Jul-Aug;38(4):1213-24. PubMed PMID: 20925993.
  9. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 Jan;24(1):153-61. doi: 10.1359/jbmr.080901. PubMed PMID: 18767928.
  10. Kalden JR, Antoni C, Alvaro-Gracia JM, Combe B, Emery P, Kremer JM, Strand CV, Van Riel P, Smolen JS. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol. 2005 Aug;32(8):1620-31. Review. PubMed PMID: 16078347.
  11. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998 Dec;41(12):2196-204. PubMed PMID: 9870876.
  12. Alvaro-Gracia JM, Yu C, Zvaifler NJ, Firestein GS. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on fibroblast-like synoviocytes: paradoxical induction of IFN-gamma and TNF-alpha receptor expression. J Clin Immunol. 1993 May;13(3):212-8. PubMed PMID: 8391545.
  13. Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol. 1992 Aug 15;149(4):1424-31. PubMed PMID: 1380043.
  14. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, Kaushansky K, Firestein GS. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol. 1991 May 15;146(10):3365-71. PubMed PMID: 2026869.
  15. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest. 1990 Dec;86(6):1790-8. PubMed PMID: 2174906; PubMed Central PMCID: PMC329810.
  16. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990 May 1;144(9):3347-53. Erratum in: J Immunol 1990 Aug 1;145(3):1037. Alvaro-Garcia JM [corrected to Alvaro-Gracia JM]. PubMed PMID: 2109776.
  17. Sánchez A, Ossorio C, Alvaro-Gracia JM, Padilla R, Avila J. A subset of antibodies from the sera of patients with systemic lupus erythematosus react with vimentin and DNA. J Rheumatol. 1990 Feb;17(2):205-9. PubMed PMID: 1690805.
  18. Broide DH, Wasserman SI, Alvaro-Gracia J, Zvaifler NJ, Firestein GS. Transforming growth factor-beta 1 selectively inhibits IL-3-dependent mast cell proliferation without affecting mast cell function or differentiation. J Immunol. 1989 Sep 1;143(5):1591-7. PubMed PMID: 2527268.
  19. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med. 1989 Sep 1;170(3):865-75. PubMed PMID: 2504878; PubMed Central PMCID: PMC2189430.
  20. Firestein GS, Xu WD, Townsend K, Broide D, Alvaro-Gracia J, Glasebrook A, Zvaifler NJ. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med. 1988 Nov 1;168(5):1573-86. PubMed PMID: 3263464; PubMed Central PMCID: PMC2189111.